Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738620 | 0.90 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1HRH3 | |
| SCHEMBL737435 | 0.83 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1 | |
| SCHEMBL735624 | 0.81 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL736038 | 0.81 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL736517 | 0.81 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL2064673 | 0.79 | — | — | |
| SCHEMBL738738 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1KDM1A | |
| SCHEMBL736886 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1MEN1 | |
| SCHEMBL3598906 | 0.76 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1HRH3ALDH1A1KDM4E | |
| SCHEMBL1827648 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993594-B2 | IRAK inhibitors and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4351552-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794543-A | Combination therapy with SETD2 inhibitors | EPIZYME股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-110099899-B | Oxazole derivatives useful as IRAK inhibitors and process for their preparation | 里格尔药品股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230075198-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-20230062818-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-4107157-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-3532470-B1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-5272268-A | Dipeptide derivatives | SHIONOGI & CO., LTD. (JP) | 1993-12-21 | — | — | US | disclosed |
| US-5223615-A | Hypotensive agents | SHIONOGI & CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5194608-A | Hypotensive agents; inhibits renin-angiotensin system | SHIONOGI & CO., LTD. (JP) | 1993-03-16 | — | — | US | disclosed |
| EP-0468641-A2 | Renin inhibiting dipeptide derivatives, their preparation and pharmaceutical preparations containing them | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | SMN1; SMN2 2278/4885L3MBTL3 3251/4885L3MBTL1 2929/4885 |
| US-20230075198-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | FOXM1, CCNE2, CCNE1 | SMN1; SMN2 1096/4885L3MBTL3 491/4885L3MBTL1 640/4885 |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | SMN1; SMN2 2656/4885L3MBTL3 2714/4885L3MBTL1 2263/4885 |
| US-11993594-B2 | IRAK inhibitors and method for making and using | IRAK1, IRAK2, IRAK3 | SMN1; SMN2 1182/4885L3MBTL3 2060/4885L3MBTL1 1474/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | SMN1; SMN2 2240/4885L3MBTL3 2533/4885L3MBTL1 2157/4885 |
| US-20230062818-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | SMN1; SMN2 1182/4885L3MBTL3 2060/4885L3MBTL1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.